Global Clinical Site Accreditation Launches
Global Clinical Site Accreditation (GCSA) has launched with a commitment aimed at increasing clinical research and trial capacity and quality in the UK, as well as globally. GCSA awards a certification mark through an evidence-based approach.
“As a global clinical research organization, Parexel is focused on working with sites as a partner in the clinical development process,” said Agnieszka Gackowska, Senior Director, Global Site Solutions. “To this end, the ability to pivot in pandemic situations and conduct trials in potentially unpredictable situations—implementing new approaches like decentralized clinical trials—is key...as we work together to bring new therapies to patients in need.”
GCSA is an assessment, improvement, and accreditation organization. A collaboration between Future Shaping Holdings Ltd, the parent company of IAOCR, and Develop Consulting.
For more information, click here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Obe-Cel Achieves High Response Rates, Durable Outcomes in r/r B-Cell Acute Lymphoblastic Leukemia
December 3rd 2024CAR T-cell therapy obecabtagene autoleucel produced high response rates, durable outcomes, and low toxicity in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, especially benefiting those with low-to-intermediate bone marrow burden.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Opdivo plus Yervoy Significantly Outperforms Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
December 2nd 2024Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.
